Abstract
Pulmonary arterial hypertension (PAH) is a severe, progressive pulmonary vasculopathy (Group 1 Pulmonary Hypertension (PH 1)) that complicates the course of many connective tissue diseases (CTD) and significantly impacts the quality and length of life of patients. Due to the various tissues that can be affected by CTD, detailed testing is required to differentiate true PAH from other types of pulmonary hypertension caused by CTD such as left heart disease (Group 2 PH), pulmonary parenchymal disease (Group 3 PH), and chronic thromboembolic pulmonary hypertension (Group 4 PH). CTD-associated PAH is most frequently seen in systemic sclerosis but can also be seen with systemic lupus erythematosus, mixed connective tissues disease, primary Sjogren's syndrome, and inflammatory myopathies. This review discusses the epidemiology of CTD-associated PAH, outlines the complex approach to obtaining a diagnosis, and finishes with an in-depth discussion on the current treatment paradigm with a focus on the pharmacological options available to patients. Focus is placed on the challenges faced in the treatment of CTD-associated PAH, in particular the decreased efficacy and poorer tolerance of pharmacological therapies and includes a discussion on the future investigational treatments that may alter the landscape of therapy. Despite significant advances over the past few decades with new medications and more aggressive treatment algorithms, patients with CTD-associated PAH are less likely to meet treatment targets and continue to have inferior survival compared to those with idiopathic PAH. This review concludes with our opinions on the current state of CTD-associated PAH, highlighting factors that lead to disparate outcomes compared to other forms of PAH, and a discussion on further improvements that may increase quality of life and survival for patients with CTD-associated PAH.

This publication has 118 references indexed in Scilit: